Observational Study
Copyright ©The Author(s) 2016.
World J Hepatol. Aug 8, 2016; 8(22): 949-956
Published online Aug 8, 2016. doi: 10.4254/wjh.v8.i22.949
Table 2 Percentage of sustained virological response according to demographics and clinical characteristics
RVR166.5%
HCV-RNA negative at EOT70.1%
Relapse27.3%
SVR 12362.7%
Age
< 50 yr67.4%
50-65 yr63.1%
> 65 yr55.3%
Previous treatment
Naive65.7%
Relapser73.7%
Partial responder67.2%
Null responder55.1%
Fibrosis (%)
F172.7%
F273.4%
F363.3%
F453.4%
F4 > 65 yr43.8%
1HCV-RNA negative at week 4;
2Those who achieved EOT but had HCV-RNA positive at week 12;
3HCV-RNA negative 12 wk after the EOT. RVR: Rapid virological response; EOT: End of treatment; SVR: Sustained virological response; HCV: Hepatitis C virus.
  • Citation: CLEO Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D’Adamo G, D’Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol 2016; 8(22): 949-956
  • URL: https://www.wjgnet.com/1948-5182/full/v8/i22/949.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v8.i22.949